Staphylococcus

1. Introduction & General Properties

• The Family: Belongs to the family Micrococcaceae, which is distinguished from Streptococcaceae by being catalase-positive.
• History: The genus was named by Sir Alexander Ogston in 1881.
• Morphology: They are Gram-positive, spherical cocci (0.8 to 0.9 µm in diameter) arranged in grape-like clusters. Cluster formation occurs because cell division takes place in three planes, with daughter cells tending to remain close together. They are non-motile, non-sporing, and rarely capsulated.
• Carriage: Asymptomatic carriage of Staphylococcus aureus is found in up to 40% of healthy individuals. The anterior nares is the most common site of colonization, followed by the skin, axilla, groins, and perineum.

---

2. Cultural Characteristics & Pigmentation

• Growth Conditions: Aerobic and facultative anaerobic; grows readily on simple media at an optimum temperature of 37°C and pH 7.4.
• Nutrient Agar: Produces circular, smooth, shiny, opaque colonies (2 to 4 mm, pinhead size). Pathogenic strains produce a characteristic golden-yellow pigment due to beta-carotene.
  • High-Yield Exam Point: Pigment production occurs optimally at room temperature (20° to 25°C) and strictly under aerobic conditions on solid media in the presence of light. Incorporation of 1% glycerol monoacetate or milk agar enhances pigmentation.
• Blood Agar: Shows pinhead-sized colonies with a narrow, clear zone of beta-hemolysis.
• MacConkey Agar: Produces minute, pink lactose-fermenting colonies.
• Selective Media:
  • Mannitol Salt Agar (MSA): Contains 7.5% NaCl, which inhibits most other bacteria. S. aureus ferments mannitol, turning the phenol red indicator yellow.
  • Salt milk agar (8% to 10% NaCl) and Ludlam's lithium chloride/tellurite medium.
• Micrococcus vs. Staphylococcus (Hugh & Leifson’s O-F Test): Staphylococcus ferments glucose fermentatively, while Micrococcus utilizes it oxidatively.

---

3. Antigenic Structure & Surface Virulence Factors

• Peptidoglycan: A thick, rigid cell wall component that elicits IL-1 production by monocytes and acts as a chemoattractant for neutrophils.
• Teichoic Acid: Polymers of ribitol/glycerol phosphate linked to peptidoglycan. It facilitates mucosal attachment and protects the cocci from complement-mediated opsonization.
• Protein A: A major cell wall component of S. aureus (classically the Cowan 1 strain).
  • High-Yield Mechanism: It binds strongly to the Fc portion of IgG molecules, leaving the Fab portion free to combine with specific antigens. This is the biological basis of the co-agglutination reaction used in diagnostic kits. It also acts as a B-cell mitogen and is antiphagocytic.
• Clumping Factor (Bound Coagulase) vs. Free Coagulase:

Property	Clumping Factor (Bound Coagulase)	Free Coagulase (Coagulase Factor)
Location	Bound to the bacterial cell wall surface.	Secreted outside the bacterial cell.
Heat Stability	Heat-stable.	Heat-labile.
CRF Requirement	Does not require Coagulase Reacting Factor (CRF).	Requires CRF in host plasma to convert fibrinogen to fibrin.
Diagnostic Test	Slide coagulase test (demonstrates clumping).	Tube coagulase test (demonstrates clot formation).

---

4. Extracellular Toxins & Enzymes

• Hemolysins: Produces four distinct types (alpha, beta, gamma, delta).
  • Alpha-hemolysin: Rapidly lyses rabbit and sheep erythrocytes; it is cardiotoxic, leukocidal, and dermo-necrotoxic.
  • Beta-hemolysin: A sphingomyelinase that lyses sheep RBCs (not human/rabbit) and exhibits the classic "hot-cold" phenomenon (hemolysis is enhanced by incubation at 37°C followed by chilling at 4°C).
• Leucocidins (Panton-Valentine Toxin / PVL): A bicomponent toxin (F and S components) that damages polymorphonuclear leukocytes (PMNs) and macrophages. It is strongly associated with Community-acquired MRSA (CA-MRSA) skin and soft tissue infections.
• Synergohymenotropic Toxins: Bicomponent membrane-active toxins composed of gamma-hemolysin and PVL.
• Epidermolytic (Exfoliative) Toxin: Exists as two proteins (Type A is heat-stable/chromosomal; Type B is heat-labile/plasmid-mediated).
  • Clinical Impact: Causes Scalded Skin Syndrome (SSSS) by separating the epidermal layers (positive Nikolsky’s sign). Severe forms include Ritter’s disease in newborns and Toxic Epidermal Necrolysis (TEN) in adults; milder forms include pemphigus neonatorum and bullous impetigo.
• Enterotoxins: Produced by nearly 50% of clinical isolates.
  • Pathogenesis: Causes classical Staphylococcal Food Poisoning (most commonly Type A). It is highly heat-stable (not destroyed by boiling) and trypsin-resistant.
  • Clinical Presentation: Ingestion of preformed toxin in contaminated dairy or meat products leads to rapid onset of nausea, projectile vomiting, and diarrhea within 1 to 6 hours. The emetic effect is mediated through vagus nerve and vomiting center stimulation.
• Toxic Shock Syndrome Toxin-1 (TSST-1): Formerly known as enterotoxin F or pyogenic exotoxin C.
  • Pathogenesis: Acts as a Superantigen, non-specifically binding MHC class II and Vβ regions of T-cell receptors, triggering a massive cytokine storm (IL-1, TNF).
  • Clinical Presentation: Classically associated with the use of vaginal tampons in menstruating women. Presents with high fever, scarlatiniform rash, hypotension, and multi-organ failure.
  • Treatment: Clindamycin is added to therapy because it actively halts toxin synthesis.

---

5. Clinical Syndromes

• Cutaneous Infections: Folliculitis, furuncles (boils), carbuncles, impetigo, wound infections, and mastitis.
• Tropical Pyomyositis: S. aureus is the overall most common cause of deep skeletal muscle abscesses in the tropics. (Note: S. pyogenes causes acute bacterial myositis).
• Deep-Seated Infections:
  • Osteomyelitis & Septic Arthritis: The most common bacterial cause (frequently affecting the knee joint).
  • Endocarditis: A rapid, highly destructive acute infective endocarditis. In intravenous drug abusers, it classically affects the right-sided tricuspid valve.
  • Pneumonia: Rare, but classically occurs as a severe secondary bacterial cavitating pneumonia following influenza, frequently demonstrating characteristic pneumatoceles on chest X-rays.

---

6. Diagnostic & Biochemical Confirmation

1. Catalase Test: Positive (GPC in clusters).
2. Coagulase Test: Positive.
3. Mannitol Fermentation: Positive.
4. DNAse Test: Positive.
5. Phosphatase Test: Positive. Inoculated on phenolphthalein diphosphate agar; when exposed to ammonia vapor, colonies turn bright pink.

---

7. Drug Resistance Patterns (Crucial for PG Exams!)

A. Penicillin Resistance (90% of strains)

• Mechanism: Production of plasmid-controlled beta-lactamase (penicillinase) which inactivates penicillin.
• Transfer: Transferred between strains primarily by transduction (bacteriophage-mediated).

B. MRSA (Methicillin-Resistant S. aureus)

• Mechanism: Mediated by the chromosomal mecA gene, located on a 30 to 50 Kb transposon-like DNA segment. It encodes a novel transpeptidase, PBP2a (or PBP2'), which has a remarkably low binding affinity for beta-lactam antibiotics, allowing cell wall cross-linking to continue even in their presence.
• Diagnostic Surrogate: Cefoxitin disc diffusion is utilized as the preferred surrogate screening marker. Alternatively, PCR for the mecA gene provides definitive detection.
• Treatment: Vancomycin is the drug of choice. Ceftobiprole is a unique fifth-generation cephalosporin with anti-MRSA activity.

C. VISA & VRSA (Vancomycin-Resistant Strains)

• VISA (Intermediate): Due to cell wall remodeling leading to an increased thickness of the peptidoglycan cell wall, trapping vancomycin molecules.
• VRSA (Resistant): Mediated by the vanA or vanB genes acquired via horizontal gene transfer from Vancomycin-Resistant Enterococci (VRE).

---

8. Coagulase-Negative Staphylococci (CoNS)

A. Staphylococcus epidermidis

• Epidemiology: Represents 60% to 70% of CoNS isolates and is part of the normal skin flora.
• Pathogenesis: Produces an extracellular polysaccharide matrix (slime/biofilm). This allows the organism to adhere tenaciously to prosthetic materials.
• Clinical Import: The leading cause of infections associated with intravenous central lines (CVP), prosthetic heart valves, cardiac shunts, and artificial joints.
• Novobiocin Status: Characteristically sensitive to Novobiocin.

B. Staphylococcus saprophyticus

• Clinical Import: A major cause of acute urinary tract infections (UTIs) in young, sexually active females.
• Novobiocin Status: Highly resistant to Novobiocin, which rapidly distinguishes it from S. epidermidis.

---

9. Laboratory Diagnosis: Identifying the Culprit

The clinical laboratory utilizes a systematic approach to identify staphylococcal species:

1. Specimen Collection: Samples include pus aspirates, blood for culture, or swabs from deep wounds.
2. Microscopy: Gram staining to identify Gram-positive clusters among polymorphonuclear leucocytes.
3. Biochemical Identification: The Coagulase test is the definitive tool to distinguish the highly pathogenic S. aureus (coagulase-positive) from the less virulent CoNS (e.g., S. epidermidis).
4. Phenotypic MRSA Detection: The Cefoxitin disc diffusion test is the standard laboratory method for detecting MRSA, as Cefoxitin is a potent inducer of the mecA gene.

---

💡 Post-Turn Examination Booster

• Co-agglutination ligand: Protein A.
• Menstrual TSS toxin: TSST-1.
• Non-menstrual TSS toxin: Enterotoxins B & C.
• Surrogate marker for MRSA: Cefoxitin.
• CA-MRSA associated toxin: Panton-Valentine Leukocidin (PVL).
• Hot-cold phenomenon: Beta-hemolysin.
• Bacterial typing of S. aureus: Phage typing (pattern method).

---